Chong Kun Dang Pharmaceutical Corp
KRX:185750
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
94 000
133 000
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Chong Kun Dang Pharmaceutical Corp
Chong Kun Dang Pharmaceutical Corp
Operating Income
Chong Kun Dang Pharmaceutical Corp
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Chong Kun Dang Pharmaceutical Corp
KRX:185750
|
Operating Income
₩246.6B
|
CAGR 3-Years
26%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
Yuhan Corp
KRX:000100
|
Operating Income
₩72.6B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
44%
|
CAGR 10-Years
0%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Operating Income
-₩37.5B
|
CAGR 3-Years
46%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Operating Income
₩262.4B
|
CAGR 3-Years
68%
|
CAGR 5-Years
25%
|
CAGR 10-Years
16%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Operating Income
₩4.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-14%
|
|
|
C
|
Celltrion Pharm Inc
KOSDAQ:068760
|
Operating Income
₩29.3B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
24%
|
CAGR 10-Years
15%
|
|
Chong Kun Dang Pharmaceutical Corp
Glance View
Chong Kun Dang Pharmaceutical Corp. engages in the manufacture, distribution, research, and development of pharmaceuticals. The company is headquartered in Seoul, Seoul. The company went IPO on 2013-12-06. The firm is mainly involved in the production and sale of prescription drugs such as antidiabetic treatments, cerebrovascular disease treatments, hypertension treatments and hyperlipidemia therapies. In addition, the Company provides over the counter (OTC) drugs including penzal, prefermine and modcol; quasi-drugs including insecticides and hair dyes; and health functional food. The firm sells products in domestic and overseas markets.
See Also
What is Chong Kun Dang Pharmaceutical Corp's Operating Income?
Operating Income
246.6B
KRW
Based on the financial report for Dec 31, 2023, Chong Kun Dang Pharmaceutical Corp's Operating Income amounts to 246.6B KRW.
What is Chong Kun Dang Pharmaceutical Corp's Operating Income growth rate?
Operating Income CAGR 5Y
27%
Over the last year, the Operating Income growth was 124%. The average annual Operating Income growth rates for Chong Kun Dang Pharmaceutical Corp have been 26% over the past three years , 27% over the past five years .
You don't have any saved screeners yet
